MYBPC3 gene therapy(Affinia Therapeutics)

N/A

Report date: 2024/11/12 15:49:55

Base Information

Drug NameMYBPC3 gene therapy(Affinia Therapeutics)
Drug Alias NameATC-0187
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionMyosin-binding protein C, cardiac-type gene transference
TargetsMyosin-binding protein C, cardiac-type
Therapy Area/IndicationsCardiomyopathy, Hypertrophic, Familial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffinia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffinia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCardiomyopathy, Hypertrophic, Familial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A